Autologous hematopoietic stem cell transplant (aHSCT) is superior to Gilenya (fingolimod) and Tysabri (natalizumab) at preventing relapses and reducing disability in people with highly active relapsing-remitting multiple sclerosis (RRMS).
In turn, aHSCT appears to be as effective as Ocrevus (ocrelizumab) in RRMS patients and also was not superior to Tysabri in people with progressive MS. These are the findings of retrospective and comparative analyses of patients with similar demographic and clinical parameters before receiving either aHSCT or approved disease-modifying therapies (DMTs). The results were shared in two oral presentations at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held Oct. 26–28 both virtually and in Amsterdam, the Netherlands.
Complete story: https://multiplesclerosisnewstoday.c...dmts-analyzed/
In turn, aHSCT appears to be as effective as Ocrevus (ocrelizumab) in RRMS patients and also was not superior to Tysabri in people with progressive MS. These are the findings of retrospective and comparative analyses of patients with similar demographic and clinical parameters before receiving either aHSCT or approved disease-modifying therapies (DMTs). The results were shared in two oral presentations at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held Oct. 26–28 both virtually and in Amsterdam, the Netherlands.
Complete story: https://multiplesclerosisnewstoday.c...dmts-analyzed/